Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICIDâ„¢ Phase 3 Data

May 9, 2011 By Bio-Medicine.Org

CHICAGO, May 9, 2011 /PRNewswire/ — Optimer Pharmaceuticals,
Inc. (NASDAQ:
OPTR) today announced the presentation of two abstracts at the
2011 Digestive Disease Week (DDW) conference highlighting
additional analyses of data from Phase 3 trials of DIFICID™
(fidaxomicin), an investigational product for the treatment of
Clostridium difficile infection (CDI).

(Logo:
http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The first analysis aimed to identify risk factors associated
with early recurrence (a relapse within the first two weeks after
end of therapy) compared to late recurrence (a relapse during the
third and fourth weeks after end of therapy). Data presented by
Kathleen Mullane, PharmD, D.O., Associate Professor of Medicine at
The University of Chicago Department of Medicine, demonstrated that
the majority of recurrences occurred within two weeks of completing
initial therapy (129/190, 67.9%). Treatment with DIFICID was
associated with a 66% reduction of early recurrence compared with
vancomycin (7.4% vs 19.3%, p<0.001), and late recurrence was the
same in both treatment arms. In addition, elevated white blood cell
counts and low albumin levels at the end of treatment and exposure
to concomitant antibiotics during the follow-up period were
associated with a higher risk of late recurrence.  The study
titled “Risk of Recurrence and Time to Recurrence Following
Treatment of Clostridium difficile Infection: Patient
Characteristics and the Differential Effect of Fidaxomicin vs.
Vancomycin,” was presented on May 7.

“As many as 30 percent of patients initially treated for CDI
will experience recurrent disease, or the persistence of CDI
symptoms following initial treatment. This can cause significant
loss of work productivity, keep people from their daily lives and,
in some cases, cause repeated hospitalizations,” said Dr.
Mullane.

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech